Cell and Gene Therapy Access Thailand: A Breakthrough Shift From Trials to Real-world Care

Regulation is a key bridge between trials and patient availability. The 2026 review notes the Thai FDA has been proactive in addressing Advanced Therapy Medicinal Products (ATMPs). It currently applies existing biological-product guidelines to ATMPs while dedicated ATMP guidance is under development, and this approach already supports approval of clinical trials and marketing authorization. The review also emphasizes the value of internationally legible oversight, recommending alignment of core technical requirements such as CMC for vectors and cell substances, GCP for decentralized trials, and pharmacovigilance with ICH-based standards as implemented by the FDA and the EMA. It further points to the need for clear guidance on cross-border sample and data transfer, genetically derived data handling, and use of foreign real-world evidence.

Market Momentum Shows the Ecosystem Expanding Beyond Trials

Thailand’s clinical-trial activity is also being quantified in market tracking, which helps show the direction of travel. Grand View Research estimates the Thailand cell and gene therapy clinical trials market generated USD 120.4 million in 2025 and is expected to reach USD 355.5 million by 2033, with a CAGR of 14.3% from 2026 to 2033. In 2025, Phase III was the largest revenue-generating phase, and Phase III held a 63.54% revenue share that year. The same source states Thailand accounted for 1.0% of the global cell and gene therapy clinical trials market in 2025. These figures do not prove access on their own, but they signal rising operational throughput that can support broader treatment availability.

Access also hinges on whether therapies can be produced and supported locally and regionally. Grand View Research estimates Thailand’s cell and gene therapy CDMO market generated USD 46.8 million in 2024 and is expected to reach USD 299.4 million by 2033, growing at a 23.3% CAGR from 2025 to 2033. Pre-clinical was the largest revenue-generating phase in 2024, with a 77.56% revenue share, and the same segment is described as the most lucrative and fastest-growing during the forecast period. The report also says Thailand accounted for 1.1% of the global cell and gene therapy CDMO market in 2024. It lists Boehringer Ingelheim GmbH, Lonza AG, and Thermo Fisher Scientific, Inc. among leading companies, and describes expansion of manufacturing capabilities and capacities to meet demand.

Finally, the enabling layer—testing and adjacent therapeutic innovation—adds another access lever. Grand View Research projects Thailand’s cell and gene therapy bioanalytical testing services market will reach US$ 27.8 million by 2030, with a 7.4% CAGR. Separately, a Thailand nucleic acid-based therapeutics report values that market at approximately USD 1.2 billion and links growth to genetic research and government support, including THB 3.5 billion allocated for biotech initiatives in future. The same report cites approximately 1 in 1,000 births affected by genetic-disorder conditions such as cystic fibrosis and muscular dystrophy, and around 22,000 new cases of genetic disorders reported annually, according to the Thai Ministry of Public Health. Together, these signals describe an ecosystem that is being built to make advanced treatment more practical outside trial-only pathways.